Technical Support

InertSearch (Application Library)

Index

Application

Document No. Index

LB301 - 400 of Application List

No. Description Column
LB301 Analysis of Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) Inertsil ODS-4
LB302 Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) Inertsil ODS-4
LB303 Analysis of Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) Inertsil ODS-4
LB304 Analysis of Candesartan cilexetil (Inertsil ODS-3) (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) Inertsil ODS-3
LB305 Analysis of Candesartan cilexetil (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) Inertsil WP300 C18
LB306 Analysis of Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) Inertsil ODS-4
LB307 Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) Inertsil ODS-4
LB308 Analysis of Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) Inertsil ODS-4
LB309 Analysis of Voriconazole (Under the Condition of the Japanese Pharmacopoeia) Inertsil WP300 C18
LB310 Analysis of Voriconazole (Under the Condition of the Japanese Pharmacopoeia, Voriconazole Tablets) Inertsil WP300 C18
LB311 Analysis of Acesulfame potassium (Inertsil ODS-3) (Under the Condition of the JPE (Japanese Pharmaceutical Excipients)) Inertsil ODS-3
LB312 Analysis of Acesulfame potassium (InertSustain C18) (Under the Condition of the JPE (Japanese Pharmaceutical Excipients)) InertSustain C18
LB313 Analysis of Acesulfame potassium (Inertsil ODS-3) (Under the Condition of the JSFA-VIII (Japanese Standards of Food Additives)) Inertsil ODS-3
LB314 Analysis of Acesulfame potassium (InertSustain C18) (Under the Condition of the JSFA-VIII (Japanese Standards of Food Additives)) InertSustain C18
LB316 Simultaneous analysis of Amino acids derivatized with 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F) InertSustainSwift C18
LB317 Separation of Triacylglycerol Positional Isomer Inertsil ODS-P
LB318 Analysis of Maleic acid, Fumaric acid and Acrylic acid (InertSustainSwift C18) InertSustainSwift C18
LB319 Analysis of Maleic acid, Fumaric acid and Acrylic acid (Inertsil WP300 C18) Inertsil WP300 C18
LB321 Analysis of components of coffee (Inertsil ODS-4 ) Inertsil ODS-4
LB323 Analysis of components of coffee in canned coffee (Inertsil ODS-4 ) Inertsil ODS-4
LB324 Analysis of 16 kinds of Aldehydes (Directed by Pre-Column Method with DNPH) InertSustainSwift C18
LB325 Analysis of Glutaraldehyde (Directed by Pre-Column Method with DNPH) InertSustainSwift C18
LB326 Analysis of o-Phthalaldehyde (Directed by Pre-Column Method with DNPH) InertSustainSwift C18
LB327 Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia 16th edition) InertSustainSwift C18
LB328 Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia 16th edition supplement II) InertSustainSwift C18
LB329 Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia) InertSustainSwift C18
LB330 Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia) InertSustain C18
LB331 Analysis of Aminoglycoside Antibiotics Inertsil Amide
LB332 Analysis of Amygdalin (Inertsil Amide) Inertsil Amide
LB333 Analysis of Amygdalin (Inertsil NH2) Inertsil NH2
LB334 Analysis of Acrylamide, Acrylonitrile and Organic acids Inertsil ODS-4
LB335 Analysis of Taurine derivatized with Dansyl Chloride (DNS-Cl) Inertsil Amide
LB336 Analysis of Taurine derivatized with Dansyl Chloride (DNS-Cl) Inertsil Amide
LB337 Analysis of Glyphosate, Glufosinate and AMPA derivatized with 9-Fluorenylmethyl Chloroformate (FMOC) InertSustain C18
LB338 Analysis of Chlorhexidine gluconate solution Inertsil ODS-4
LB339 Analysis of Rebamipide (Under the Condition of the Japanese Pharmacopoeia, Rebamipide Tablets) InertSustain C18
LB340 Analysis of Chelating compounds InertSustain C18
LB341 Analysis of Furfral and 5-Hydroxymethylfurfral (InertSustain C18) InertSustain C18
LB342 Analysis of Furfral and 5-Hydroxymethylfurfral (InertSustainSwift C18) InertSustainSwift C18
LB343 Analysis of Furfral and 5-Hydroxymethylfurfral (Inertsil ODS-4) Inertsil ODS-4
LB344 Analysis of 6 kinds of monosaccharides and disaccharides InertSphere Sugar-1
LB345 Analysis of 6 kinds of monosaccharides and disaccharides InertSphere Sugar-1
LB346 Analysis of Inositol, Ribitol and Fucose InertSphere Sugar-1
LB347 Analysis of neutral sugars and amino sugars InertSphere Sugar-1
LB348 Analysis of Sodium Propionate (Inertsil ODS-3) Inertsil ODS-3
LB349 Analysis of Sodium Propionate (InertSustain C18) InertSustain C18
LB350 Analysis of 7 fatty acids (Inertsil ODS-3) Inertsil ODS-3
LB351 Analysis of 7 fatty acids (Inertsil ODS-4) Inertsil ODS-4
LB352 Analysis of 7 fatty acids (InertSustain C18) InertSustain C18
LB353 Analysis of 7 fatty acids InertSustain C18
LB354 Analysis of 7 fatty acids InertSustain C18
LB355 Analysis of 7 fatty acids InertSustain C18
LB356 Analysis of EPA and DHA (Inertsil ODS-3) Inertsil ODS-3
LB357 Analysis of EPA and DHA (Inertsil ODS-4) Inertsil ODS-4
LB358 Analysis of EPA and DHA (InertSustain C18) InertSustain C18
LB359 Analysis of EPA and DHA InertSustain C18
LB360 Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia, Roxithromycin Tablets) InertSustain C18
LB361 Analysis of Furfral and 5-Hydroxymethylfurfral (InertSustain AQ-C18) InertSustain AQ-C18
LB362 Analysis of β-blocker InertSustain AQ-C18
LB363 Analysis of Organic acid InertSustain AQ-C18
LB364 Analysis of Water-soluble Vitamins InertSustain AQ-C18
LB365 Analysis of Nucleoside and Nucleic acid base (InertSustain AQ-C18) InertSustain AQ-C18
LB366 Analysis of Nucleoside and Nucleic acid base (InertSustain AQ-C18) InertSustain AQ-C18
LB367 Analysis of Nucleoside and Nucleic acid base (InertSustain C18) InertSustain C18
LB368 Analysis of Nucleoside and Nucleic acid base (InertSustain C18) InertSustain C18
LB369 Analysis of Capsaicin (Under the Condition of the Japanese Pharmacopoeia, Capsicum Tincture) InertSustain Phenyl
LB370 Analysis of Prednisolone (Under the Condition of European Pharmacopoeia 8.2) Inertsil ODS-3
LB371 Analysis of Amlodipine besilate (Under the Condition of the Japanese Pharmacopoeia, Amlodipine Besilate Orally Disintegrating Tablets) InertSustainSwift C18
LB372 Analysis of Cyclophosphamide (Under the Condition of the Japanese Pharmacopoeia, Cyclophosphamide Tablets) InertSustainSwift C18
LB373 Analysis of Cyclophosphamide (Under the Condition of the Japanese Pharmacopoeia, Cyclophosphamide Tablets) InertSustainSwift C18
LB374 Analysis of Ampiroxicam (Under the Condition of the Japanese Pharmacopoeia) Inertsil WP300 C18
LB375 Analysis of Lidocaine InertSustain C18
LB376 Analysis of Hexamethylenetetramine (HMTA) Inertsil HILIC
LB377 Analysis of 13 kinds of Aldehydes (Directed by Pre-Column Method with DNPH) InertSustain AQ-C18 HP
LB378 Analysis of Hippuric Acids InertSustain AQ-C18 HP
LB379 Analysis of Hippuric Acids InertSustain AQ-C18 HP
LB380 Analysis of ATP related compounds InertSustain AQ-C18
LB381 Analysis of Angiotensin II receptor blockers (InertSustain AQ-C18) InertSustain AQ-C18
LB382 Analysis of Angiotensin II receptor blockers (InertSustain C18) InertSustain C18
LB383 Analysis of Angiotensin II receptor blockers (InertSustainSwift C18) InertSustainSwift C18
LB384 Analysis of Angiotensin II receptor blockers (Inertsil ODS-3) Inertsil ODS-3
LB385 Analysis of Angiotensin II receptor blockers (Inertsil ODS-4) Inertsil ODS-4
LB386 Analysis of Angiotensin II receptor blockers (Inertsil ODS-SP) Inertsil ODS-SP
LB387 Analysis of 12 Drugs (InertSustain AQ-C18 HP) InertSustain AQ-C18 HP
LB388 Analysis of 12 Drugs (InertSustain C18 HP) InertSustain C18 HP
LB389 Analysis of 12 Drugs (InertSustainSwift C18 HP) InertSustainSwift C18 HP
LB390 Analysis of 12 Drugs (Inertsil ODS-4) Inertsil ODS-4
LB391 Analysis of 12 Drugs (Inertsil ODS-3) Inertsil ODS-3
LB392 Analysis of Methacrylic acid (InertSustain AQ-C18) InertSustain AQ-C18
LB393 Analysis of Methacrylic acid (InertSustainSwift C18) InertSustainSwift C18
LB394 Analysis of Methacrylic acid (InertSustain C18) InertSustain C18
LB395 Analysis of Acetaminophen and Caffeine InertSustainSwift C18
LB396 Analysis of Oligonucleotide InertSustainBio C18
LB397 Analysis of Glyphosate, Glufosinate and AMPA derivatized with 9-Fluorenylmethyl Chloroformate (FMOC) InertSustainSwift C18
LB398 Analysis of 9 Drugs (InertSustain AQ-C18) InertSustain AQ-C18
LB399 Analysis of 9 Drugs (InertSustainSwift C18) InertSustainSwift C18
LB400 Analysis of 9 Drugs (InertSustain C18) InertSustain C18